Sept. 11, 2026
West Coast Biotech & Life Sciences Reporter
Jonathan Wosen is STAT’s West Coast biotech & life sciences reporter. You can reach Jonathan on Signal at jwosen.27.
Scholar Rock on Friday received Food and Drug Administration approval for the first-ever therapy that targets the loss of muscle in spinal muscle atrophy, raising hopes that patients with the rare neurological disorder might have a better chance of moving and walking independently.
The FDA approved the drug, Isembyld, for use in adults and children 2 years and older who are currently receiving SMA therapies that target SMN2, a key gene for neurons that control movement. Alate-stageclinical trial found that, when combined with an SMN2-targeting drug, Isembyld caused young patients’ motor skills to improve after a year, while those in a placebo group declined, a difference that was statistically significant.
Advertisement
“Today’s FDA approval of Isembyld marks a defining moment for the SMA community,” said David Hallal, CEO of Scholar Rock, in a pressrelease. “After decades of failed industry-wide efforts to unlock the potential of myostatin inhibition, Scholar Rock has delivered a therapeutic breakthrough.”
STAT+ Exclusive Story
Already have an account?Log in
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account?Log in
Monthly
$39
Totals $468 per year
$39/monthGet StartedTotals $468 per year
Starter
$30
for 3 months, then $399/year
$30 for 3 monthsGet StartedThen $399/year
Annual
$399
Save 15%
$399/yearGet StartedSave 15%
11+ Users
Custom
Savings start at 25%!
Request A QuoteRequest A QuoteSavings start at 25%!
2-10 Users
$300
Annually per user
$300/yearGet Started$300 Annually per user
View All PlansTo read the rest of this story subscribe to STAT+.
SubscribeLog InFDA,
Pharmaceuticals,
research,
STAT+Submit a correction requestReprintsWest Coast Biotech & Life Sciences Reporter
Jonathan Wosen is STAT’s West Coast biotech & life sciences reporter. You can reach Jonathan on Signal at jwosen.27.
STAT+ Newsletter
Senior writer Adam Feuerstein's unfiltered, uncompromising analysis on the biotech world
